High Evidence Drugs
Priority candidates for clinical evaluation
Evidence Standards
| Level | Definition | Clinical Significance |
|---|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews | Strong support, consider clinical use |
| L2 | Single RCT or multiple Phase 2 trials | Moderate support, design validation trials |
Drug List
L1 Level (81 drugs)
| Drug Name | Predictions | Link |
|---|---|---|
| Aceclofenac | 10 | View Report |
| Acetylcysteine | 5 | View Report |
| Acyclovir | 5 | View Report |
| Adalimumab | 5 | View Report |
| Agomelatine | 10 | View Report |
| Anastrozole | 6 | View Report |
| Atenolol | 5 | View Report |
| Beclomethasone Dipropionate | 5 | View Report |
| Bortezomib | 5 | View Report |
| Budesonide | 5 | View Report |
| Bupropion | 10 | View Report |
| Busulfan | 10 | View Report |
| Capecitabine | 5 | View Report |
| Carbamazepine | 5 | View Report |
| Carbidopa | 5 | View Report |
| Carboplatin | 10 | View Report |
| Cefoperazone | 10 | View Report |
| Ceftazidime | 5 | View Report |
| Celecoxib | 5 | View Report |
| Clarithromycin | 5 | View Report |
| Clobetasol Propionate | 5 | View Report |
| Clonidine | 10 | View Report |
| Daunorubicin | 10 | View Report |
| Desonide | 10 | View Report |
| Dexlansoprazole | 10 | View Report |
| Dexpanthenol | 7 | View Report |
| Doxorubicin | 10 | View Report |
| Emicizumab | 10 | View Report |
| Ethinylestradiol | 5 | View Report |
| Ezetimibe | 5 | View Report |
| Fluoxetine | 10 | View Report |
| Fluvoxamine | 10 | View Report |
| Gimeracil | 10 | View Report |
| Haloperidol | 10 | View Report |
| Ibuprofen | 5 | View Report |
| Ifosfamide | 10 | View Report |
| Iloprost | 9 | View Report |
| Indomethacin | 10 | View Report |
| Insulin Aspart | 10 | View Report |
| Insulin Degludec | 6 | View Report |
| Insulin Detemir | 10 | View Report |
| Insulin Glulisine | 10 | View Report |
| Insulin Human | 5 | View Report |
| Ipilimumab | 2 | View Report |
| Irbesartan | 5 | View Report |
| Iron | 5 | View Report |
| Lamivudine | 5 | View Report |
| Laronidase | 2 | View Report |
| Letrozole | 10 | View Report |
| Levodopa | 5 | View Report |
| Magnesium Sulfate | 10 | View Report |
| Mefenamic Acid | 8 | View Report |
| Mercaptopurine | 10 | View Report |
| Metronidazole | 5 | View Report |
| Nitric Oxide | 10 | View Report |
| Obinutuzumab | 3 | View Report |
| Olaparib | 1 | View Report |
| Oteracil | 10 | View Report |
| Pantoprazole | 6 | View Report |
| Pegaspargase | 10 | View Report |
| Pertuzumab | 10 | View Report |
| Prednisolone Acetate | 10 | View Report |
| Pregabalin | 5 | View Report |
| Ranibizumab | 10 | View Report |
| Ranitidine | 10 | View Report |
| Simvastatin | 5 | View Report |
| Tacrolimus | 3 | View Report |
| Tamoxifen | 10 | View Report |
| Tazobactam | 2 | View Report |
| Tegafur | 10 | View Report |
| Telmisartan | 5 | View Report |
| Temozolomide | 2 | View Report |
| Teriflunomide | 1 | View Report |
| Ticagrelor | 10 | View Report |
| Tiotropium | 10 | View Report |
| Tipiracil | 10 | View Report |
| Tramadol | 10 | View Report |
| Trastuzumab | 10 | View Report |
| Triazolam | 1 | View Report |
| Uracil | 10 | View Report |
| Vonoprazan | 10 | View Report |
L2 Level (60 drugs)
| Drug Name | Predictions | Link |
|---|---|---|
| Acetazolamide | 10 | View Report |
| Alpha-Tocopherol Acetate | 10 | View Report |
| Amphotericin B | 5 | View Report |
| Arsenic Trioxide | 10 | View Report |
| Ascorbic Acid | 10 | View Report |
| Atezolizumab | 10 | View Report |
| Brentuximab Vedotin | 10 | View Report |
| Cabazitaxel | 10 | View Report |
| Cabozantinib | 10 | View Report |
| Caffeine | 5 | View Report |
| Calcitriol | 7 | View Report |
| Chloramphenicol | 5 | View Report |
| Cholecalciferol | 7 | View Report |
| Citalopram | 5 | View Report |
| Clavulanic Acid | 5 | View Report |
| Clofarabine | 10 | View Report |
| Clomipramine | 10 | View Report |
| Danazol | 10 | View Report |
| Dasatinib | 10 | View Report |
| Dexamethasone | 5 | View Report |
| Dextromethorphan | 6 | View Report |
| Diazepam | 10 | View Report |
| Epinephrine | 4 | View Report |
| Erenumab | 1 | View Report |
| Erythromycin | 5 | View Report |
| Everolimus | 5 | View Report |
| Fluticasone Furoate | 8 | View Report |
| Gemcitabine | 10 | View Report |
| Guaifenesin | 5 | View Report |
| Imatinib | 10 | View Report |
| Insulin Glargine | 5 | View Report |
| Latanoprost | 10 | View Report |
| Ledipasvir | 10 | View Report |
| Levonorgestrel | 6 | View Report |
| Lorazepam | 10 | View Report |
| Magnesium Carbonate | 10 | View Report |
| Magnesium Hydroxide | 5 | View Report |
| Megestrol Acetate | 10 | View Report |
| Mesalazine | 7 | View Report |
| Methotrexate | 5 | View Report |
| Moclobemide | 2 | View Report |
| Mycophenolate Mofetil | 10 | View Report |
| Norfloxacin | 5 | View Report |
| Oxaliplatin | 4 | View Report |
| Paclitaxel | 5 | View Report |
| Pimecrolimus | 4 | View Report |
| Prilocaine | 10 | View Report |
| Prochlorperazine | 10 | View Report |
| Propofol | 5 | View Report |
| Revefenacin | 2 | View Report |
| Rimegepant | 6 | View Report |
| Risankizumab | 10 | View Report |
| Salbutamol | 10 | View Report |
| Sirolimus | 10 | View Report |
| Sunitinib | 10 | View Report |
| Topotecan | 10 | View Report |
| Trabectedin | 1 | View Report |
| Valproic Acid | 10 | View Report |
| Vildagliptin | 10 | View Report |
| Vinorelbine | 10 | View Report |
How Evidence Levels Are Determined
Evidence levels are assigned based on the quality and quantity of clinical evidence:
- Clinical Trials: Phase 3 RCTs carry the highest weight
- Systematic Reviews: Meta-analyses of multiple studies
- Study Design: Randomized controlled trials > observational studies
- Sample Size: Larger studies provide stronger evidence
Disclaimer
Drug repurposing predictions are for research purposes only. These predictions have not been clinically validated and should not be used for medical decisions. Always consult healthcare professionals.
Drug repurposing predictions are for research purposes only. These predictions have not been clinically validated and should not be used for medical decisions. Always consult healthcare professionals.